연구동향 분석

Understanding the Mechanism of Action and Clinical Implications of Anti-Obesity Drugs Recently Approved in Korea

김경곤 2019년

논문상세정보
인용/피인용
' Understanding the Mechanism of Action and Clinical Implications of Anti-Obesity Drugs Recently Approved in Korea' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • bupropion
  • liraglutide
  • lorcaserin
  • naltrexone
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
32 0

0.0%

' Understanding the Mechanism of Action and Clinical Implications of Anti-Obesity Drugs Recently Approved in Korea' 의 참고문헌

  • Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study
    Wadden TA [2013]
  • Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial
    Wadden TA [2011]
  • Vagal afferents mediate early satiation and prevent flavour avoidance learning in response to intraperitoneally infused exendin-4
  • The hepatic vagal nerve is receptive to incretin hormone glucagon-like peptide-1, but not to glucose-dependent insulinotropic polypeptide, in the portal vein
    Nishizawa M [1996]
  • The gut and energy balance : visceral allies in the obesity wars
    Badman MK [2005]
  • The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
    Secher A [2014]
  • Suppression of appetitive behavior in the rat by naloxone : lack of effect of prior morphine dependence
    Holtzman SG [1979]
  • Short-term use of liraglutide in the management of patients with weight regain after bariatric surgery
    Pajecki D [2013]
  • Serotonin reciprocally regulates melanocortin neurons to modulate food intake
    Heisler LK [2006]
  • Serotonin controlling feeding and satiety
    Voigt JP [2015]
  • Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors
    Lam DD [2008]
  • Schizophrenia and increased risks of cardiovascular disease
  • Role of dopamine in the regulation of proopiomelanocortin(POMC)mRNA levels in the arcuate nucleus and pituitary gland of the female rat as studied by in situ hybridization
    Tong Y [1992]
  • Rational design of a combination medication for the treatment of obesity
    Greenway FL [2009]
  • Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study
    O’Neil PM [2012]
  • Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review
    Onakpoya IJ [2016]
  • Multicenter, placebo-controlled trial of lorcaserin for weight management
    Smith SR [2010]
  • Metabolic bariatric surgery and type 2 diabetes mellitus : an endocrinologist’s perspective
    Ganguly S [2015]
  • Management of antipsychotic-related weight gain
    Maayan L [2010]
  • Liraglutide in an adolescent population with obesity : a randomized, double-blind, placebo-controlled 5-week trial to assess safety, tolerability, and pharmacokinetics of liraglutide in adolescents aged 12-17 years
    Danne T [2017]
  • Liraglutide and cardiovascular outcomes in type 2diabetes
    Marso SP [2016]
  • Liraglutide : short-lived effect on gastric emptying : long lasting effects on body weight
    Jelsing J [2012]
  • Interactions of glucagon-like peptide-1(GLP-1)with the blood-brain barrier
    Kastin AJ [2002]
  • Intensive glucose control and cardiovascular outcomes in type 2 diabetes
    Macisaac RJ [2011]
  • Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice
    Billes SK [2007]
  • Glucagon-like peptide-1receptor agonists in type 2 diabetes treatment : are they all the same
  • Glucagon-like peptide-1 evokes action potentials and increases cytosolic Ca2+ in rat nodose ganglion neurons
    Kakei M [2002]
  • GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
    Meier JJ [2012]
  • Evolution and function in serotonergic systems
    Gillette R [2006]
  • Energy expenditure by intravenous administration of glucagon-like peptide-1 mediated by the lower brainstem and sympathoadrenal system
    Osaka T [2005]
  • Endogenous glucagon-like peptide-1 suppresses high-fat food intake by reducing synaptic drive onto mesolimbic dopamine neurons
    Wang XF [2015]
  • Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial
    Davies MJ [2015]
  • Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss inpatientswithobesity:a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
  • Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes
    Hollander P [2013]
  • Effects of long-term therapy with naltrexone on body weight in obesity
    Atkinson RL [1985]
  • Effects of chronic fenfluramine administration on hypothalamic neuropeptide mRNA expression
    Choi S [2006]
  • Effectiveness and tolerability of liraglutide in patients with type 2 diabetes mellitus and obesity after bariatric surgery
  • Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes
    Horowitz M [2012]
  • Effect of serotonergic anorectics on food intake and induction of Fos in brain of mice with disruption of melanocortin 3 and/or 4 receptors
    Rowland NE [2010]
  • Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2diabetes : a randomized clinical trial
    Davies M [2017]
  • Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors : a randomized clinical trial
    Nissen SE [2016]
  • Effect of naltrexone plus bupropion on weight loss in overweight and obese adults(COR-I) : a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
    Greenway FL [2010]
  • Effect of naltrexone on food intake, hunger, and satiety in obese men
    Spiegel TA [1987]
  • Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients(CAMELLIA-TIMI 61) : a randomised, placebo-controlled trial
    Bohula EA [2018]
  • Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial
    Larsen JR [2017]
  • Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial
    Blackman A [2016]
  • Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis
    Hunter K [2012]
  • Dopaminergic regulation of pre-proNPY mRNA levels in the rat arcuate nucleus
    Pelletier G [1991]
  • Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem
    Larsen PJ [1997]
  • Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling
    Lockie SH [2012]
  • Controlled substance schedules
  • Bupropion SR enhances weight loss : a 48-week doubleblind, placebo-controlled trial
    Anderson JW [2002]
  • Biology of incretins : GLP-1 and GIP
    Baggio LL [2007]
  • Acute fenfluramine administration reduces neuropeptide Y concentrations in specific hypothalamic regions of the rat : possible implications for the anorectic effect of fenfluramine
    Rogers P [1991]
  • Activation of central melanocortin pathways by fenfluramine
    Heisler LK [2002]
  • A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors(COR-II)
    Apovian CM [2013]
  • A randomized, controlled trial of 3.0 mg of liraglutide in weight management
    Pi-Sunyer X [2015]
  • A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults : the BLOSSOM trial
    Fidler MC [2011]
  • A meta-analysis of the past 25years of weight loss research using diet, exercise or diet plus exercise intervention
    Miller WC [1997]
  • A high-resolution in vivo atlas of the human brain’s serotonin system
    Beliveau V [2017]